X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Elder Pharma Fact Sheet, Elder Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Elder Pharma Fact Sheet   (ELDER)

Here is the latest financial fact sheet of Elder Pharma. For more details, see the Elder Pharma quarterly results and Elder Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

ELDER PHARMA Price History

Price Rs 38.0
Mkt Cap Rs m 781
Vol '000 20.5
P/E X -0.2
P/CF X 2.6
EPS (TTM) Rs -220.6
% ch % 5.0
No. of shares m 20.54
% ch week % 5.0
% ch 1-mth % 27.1
% ch 12-mth % -64.5
52 week H/L Rs 118.8/20.4
(As on Sep 12, 2016 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ELDER PHARMA Financials

No. of Mths
Year Ending
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
15
Jun-13
*
12
Jun-14
*
5-Yr Chart
Click to enlarge
ELDER PHARMA EQUITY SHARE DATA
High Rs440435416416380 
Low Rs321298202202188 
Sales per share (Unadj.) Rs470.0649.8799.3799.3491.2 
Earnings per share (Unadj.) Rs31.335.240.140.1-3.2 
Diluted earnings per shareRs31.335.240.140.1-3.2 
Cash flow per share (Unadj.) Rs45.351.761.661.614.4 
Dividends per share (Unadj.) Rs3.003.00000 
Adj. dividends per shareRs3.003.000.000.000.00 
Dividend yield (eoy) %0.80.8000 
Book value per share (Unadj.) Rs307.0341.1374.5374.5376.5 
Adj. book value per shareRs307.0341.1374.5374.5376.5 
Shares outstanding (eoy) m20.5420.5420.5420.5420.54 
Bonus/Rights/Conversions  PP---- 
Price / Sales ratio x0.80.60.40.40.6 
Avg P/E ratio x12.210.47.77.7-89.3 
P/CF ratio (eoy) x8.47.15.05.019.7 
Price / Book Value ratio x1.21.10.80.80.8 
Dividend payout %9.68.5000 
Avg Mkt Cap Rs m7,8157,5286,3486,3485,833 
No. of employees `0003.63.5NANANA 
Total wages/salary Rs m1,2261,7992,3312,3312,179 
Avg. sales/employee Rs Th2,674.63,773.8NMNMNM 
Avg. wages/employee Rs Th339.7508.6NMNMNM 
Avg. net profit/employee Rs Th178.0204.3NMNMNM 
ELDER PHARMA INCOME DATA
Net Sales Rs m9,65313,34816,41716,41710,089 
Other income Rs m87265327327257 
Total revenues Rs m9,73913,61316,74416,74410,346 
Gross profit Rs m1,3311,9902,7342,734-792 
Depreciation Rs m287340441441361 
Interest Rs m2811,0161,5481,5482,756 
Profit before tax Rs m8499001,0711,071-3,653 
Minority Interest Rs m70000 
Prior Period Items Rs m80000 
Extraordinary Inc (Exp) Rs m-4515-28-283,713 
Tax Rs m177193219219125 
Profit after tax Rs m642723824824-65 
Gross profit margin %13.814.916.716.7-7.8 
Effective tax rate %20.821.420.520.5-3.4 
Net profit margin %6.75.45.05.0-0.6 
ELDER PHARMA BALANCE SHEET DATA
Current assets Rs m8,2788,7828,7918,7919,240 
Current liabilities Rs m5,8036,9579,9989,9989,998 
Net working cap to sales %25.613.7-7.4-7.4-7.5 
Current ratio x1.41.30.90.90.9 
Inventory Days Days9180545446 
Debtors Days Days10793898960 
Net fixed assets Rs m7,4258,9739,6319,63110,124 
Share capital Rs m206206206206206 
"Free" reserves Rs m5,4365,7906,1216,1215,582 
Net worth Rs m6,3077,0067,6937,6937,734 
Long term debt Rs m5,0955,8257,0397,0394,889 
Total assets Rs m17,41519,99824,92524,92522,882 
Interest coverage x4.01.91.71.7-0.3 
Debt to equity ratio x0.80.80.90.90.6 
Sales to assets ratio x0.60.70.70.70.4 
Return on assets %5.38.79.59.511.8 
Return on equity %10.210.310.710.7-0.8 
Return on capital %9.615.017.617.622.3 
Exports to sales %2.42.11.91.93.0 
Imports to sales %3.62.31.81.80.4 
Exports (fob) Rs m228280318318307 
Imports (cif) Rs m35130629129143 
Fx inflow Rs m228280318318307 
Fx outflow Rs m388334361361125 
Net fx Rs m-160-54-43-43181 
ELDER PHARMA CASH FLOW
From Operations Rs m 657 148 194 166 11,754 
From Investments Rs m -1,507 -1,711 -632 -632 -561 
From Financial Activity Rs m 2,734 433 -67 -39 -6,762 
Net Cashflow Rs m 1,885 -1,131 -506 -506 4,432 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 39.6%
Foreign collaborators 0.0%
Indian inst/Mut Fund 7.5%
FIIs 16.8%
ADR/GDR 0.0%
Free float 36.1%
Shareholders 16,479
Pledged promoter(s) holding 77.6%
 

Company Information

REGD OFF Elder House, Plot No. C-9, Dalia Indl. Estate, Off Veera Desai Road, Mumbai-53
E-MAIL s.p.date@elderindia.com WEB www.elderindia.com
TELEPHONE (022) 2673 0058 FAX (022) 2673 0051
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Intime Spectrum, C-13, Pannalal Silk Mills Compd., LBS Marg, Mumbai - 78
AUDITOR S. S. Khandelwal & Co.
CHM: J. Saxena COMP SEC: S. P. Date YEAR OF INC: 1900 BSE CODE: 532322 FV (Rs): 10 DIV YIELD (%): -

More Pharmaceuticals Company Fact Sheets:   TTK HEALTHCARE  STRIDES SHASUN LTD  MERCK LTD  WYETH LTD  SANOFI INDIA  

Compare ELDER PHARMA With:   TTK HEALTHCARE  STRIDES SHASUN LTD  MERCK LTD  WYETH LTD  SANOFI INDIA  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ELDER PHARMA

ELDER PHARMA - TEVA PHARMA COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS